BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?

The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.

By Michael Gibney • Dec. 4, 2025

4 major changes at the FDA this year

The most impactful regulatory shifts for pharma in 2025 and how the industry can take advantage of new policies. 

By Alexandra Pecci • Dec. 3, 2025

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

Hemophilia gene therapies are struggling on the market, even as innovation soars

The business case for hemophilia gene therapy still isn’t adding up due to persistent market barriers.

By Kelly Bilodeau • Dec. 3, 2025

Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons

November was a tough month for highly anticipated Alzheimer’s readouts with a GLP-1 and tau-targeting drug coming up short in late-stage trials.

By Michael Gibney • Dec. 2, 2025

A drugmaker charts a path through pharma’s ethical minefields

As the science behind pharma breakthroughs becomes more complex, bioethicists are helping companies navigate moral quandaries.

By Kelly Bilodeau • Dec. 1, 2025

Along with NIH cuts come risks to patient safety and scientific data

The abrupt withdrawal of research funds affected 74,000 clinical trial participants, including some already taking the drugs being studied.

By Kelly Bilodeau • Nov. 26, 2025

What’s next in the eye disease pipeline?

An early gene therapy breakthrough spurred investments, but can the industry maintain momentum?  

By Kelly Bilodeau • Nov. 24, 2025

As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones

Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.

By Kelly Bilodeau • Nov. 19, 2025

Amylin could reign supreme in the next wave of obesity drugs

With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.

By Alivia Kaylor • Nov. 18, 2025

Developing a path forward in cancer cachexia

Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia.

Nov. 17, 2025

The next leap in Alzheimer’s R&D is coming, but not around the corner

While a couple drugs have reached the market, their effects are still modest, and experts say a true paradigm shift is still a ways off.

By Alexandra Pecci • Nov. 17, 2025

RNAi looked doomed to fail — until Alnylam’s science chief found a way

Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

By Michael Gibney • Nov. 13, 2025

Drugs are winning approval even when trials fail — but should they?

About 10% of FDA-approved drugs in recent years have won clearance despite a trial failure, raising safety and ethical concerns.

By Kelly Bilodeau • Nov. 12, 2025

Pharma’s clinical trial diversity push faces a new threat

Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.

By Meagan Parrish • Nov. 7, 2025

Why Pfizer and Novo are duking it out over weight loss startup Metsera

A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena’s high stakes.

By Michael Gibney • Nov. 6, 2025

Chinese drugmaker becomes top trial sponsor — and other clinical trends

The industry’s top indication areas for R&D and other shifts in the clinical trial landscape last year.

By Kelly Bilodeau • Nov. 5, 2025

Imunon’s non-viral DNA candidate may have cracked the code in frontline ovarian cancer

Imunon is showing off promising phase 3 data at a gynecologic cancer conference this week.

By Alexandra Pecci • Nov. 5, 2025

Biogen’s yearslong lupus R&D journey could soon pay off

Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.

By Michael Gibney • Nov. 4, 2025

Roche taps an AI specialist to craft new brain drugs

For $55 million, Roche gains access to Manifold Bio’s drug discovery technology, which will be used to develop new “shuttles” that can get medicines across the blood-brain barrier.

By Jacob Bell • Nov. 4, 2025

One of the few late-stage ALS contenders hits a critical juncture

MediciNova has launched a potentially pivotal trial for what it hopes is a disease-modifying ALS drug.

By Meagan Parrish • Oct. 31, 2025

Corporate venture firms stepped in for drug startups during biotech funding pullback

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.

By Gwendolyn Wu • Oct. 31, 2025

What comes next for Novo Nordisk?

After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is on Novo to pull off a major about-face.

By Kelly Bilodeau • Oct. 29, 2025

Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience

A premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at revolutionary technology that fits into their own expertise.

By Michael Gibney • Oct. 28, 2025

Merck’s oncology prospects could portend a post-Keytruda future

Can the pharma giant offset potential losses from its megablockbuster with a strong suite of contenders?

By Kelly Bilodeau • Oct. 27, 2025

How limited options for lupus patients and the challenge of a complex disease drove my mission for change

Lupus is a complex disease – Biogen is seeking to develop potential new treatment options and new hope for patients.

By Youmna Lahoud, MD, FACR, Medical Director, Clinical Development Immunology at Biogen • Oct. 27, 2025